Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Assembly Biosciences Q3 2026 Results: Net Loss of $20.3M, Loss Widens

Assembly Biosciences, Inc. is a non-accelerated filer and smaller reporting company focused on therapeutic product candidates, primarily through a collaboration with Gilead Sciences. As of September 30, 2026, the company remains pre-revenue and unprofitable, relying on third-party CROs and collaborators for clinical development and manufacturing.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue3.010.8
Net income-20.3-9.2
EPS (diluted, $ a share)$-0.93$-0.72

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-72.6%
Source

10-Q filed with the SEC, NASDAQ: ASMB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Assembly Biosciences, Inc.: key numbers

Share price
$21.29Close, Nov 16
Market cap
$436M
Shares outstanding
20.48MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Assembly Biosciences, Inc.

All →
4:06 PM ET 8-K
Financial Results

Assembly Biosciences Financial Results

Assembly Biosciences reported Q3 2026 financial results and announced the receipt of a $75 million collaboration extension fee from Gilead Sciences, extending its cash runway into 2029. The company also exercised its option to share 40% of U.S. development costs and profits for the HSV helicase primase inhibitor program and initiated a Phase 2 study for ABI-6250 in chronic hepatitis delta virus.

Counterparty
Gilead Sciences, Inc.

“This quarter, we rapidly advanced our liver disease program by initiating the Phase 2 study of ABI-6250 in chronic hepatitis delta virus and preparing for our Phase 2 study in cholestatic liver diseases, which we expect to begin in the first quarter next year. Alongside that progress, we elected to share U.S. costs and profits for the HSV helicase primase inhibitor program under our collaboration with Gilead, a decision we believe represents a significant opportunity to build long-term value. With a strong financial position, we look forward to the continued expansion of our pipeline and advancement of the herpesvirus and liver disease programs through their respective Phase 2 studies.”

Jason Okazaki, chief executive officer and president of Assembly Bio
4:50 PM ET Form 4
Insider Selling

Assembly Biosciences PFO and PAO Jeanette M. Bjorkquist Sells $14.1K of Stock

Jeanette M. Bjorkquist, PFO and PAO, sold 718 shares of Assembly Biosciences, Inc. at $19.61 a share, worth $14.1K in total on Nov 2, 2026. Shares held after the trade: 17,682 (-3.9%).

Value
$14.1K
Shares
718
Price
$19.61
Role
PFO and PAO
Holding change
-3.9%
Trade date
Nov 2, 2026
4:45 PM ET Form 4
Insider Selling

Assembly Biosciences Chief Manufacturing Officer Nicole S. White Sells $50.3K of Stock

Nicole S. White, Chief Manufacturing Officer, sold 2,564 shares of Assembly Biosciences, Inc. at $19.61 a share, worth $50.3K in total on Nov 2, 2026. Shares held after the trade: 59,286 (-4.1%).

Value
$50.3K
Shares
2,564
Price
$19.61
Role
Chief Manufacturing Officer
Holding change
-4.1%
Trade date
Nov 2, 2026
4:35 PM ET Form 4
Insider Selling

Assembly Biosciences CMO Anuj Gaggar Sells $50.3K of Stock

Anuj Gaggar, CMO, sold 2,564 shares of Assembly Biosciences, Inc. at $19.61 a share, worth $50.3K in total on Nov 2, 2026. Shares held after the trade: 53,829 (-4.5%).

Value
$50.3K
Shares
2,564
Price
$19.61
Role
CMO
Holding change
-4.5%
Trade date
Nov 2, 2026
4:31 PM ET Form 4
Insider Selling

Assembly Biosciences CEO and President Jason A. Okazaki Sells $120K of Stock

Jason A. Okazaki, CEO and President, sold 6,133 shares of Assembly Biosciences, Inc. at $19.61 a share, worth $120K in total on Nov 2, 2026. Shares held after the trade: 195,601 (-3.0%).

Value
$120K
Shares
6,133
Price
$19.61
Role
CEO and President
Holding change
-3.0%
Trade date
Nov 2, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.